RE: Enbrel vs. VoclosporineCheck out Wyeth (acquired by Pfizer)/Amgen 1Q 2009 results for Enbrel Sales, quite substantial (RA + Psoriasis etc) even though sales Enbrel sales are down 20%, except for Wyeth was up 3% in USA only (power of marketing).
I found some interesting reading about Psoriasis treatments and why Enbrel is preferred over others like Remicade (due to more adverse events) etc. As P11 indicated, not an over abundance of long-term data on the biologics. IMO Voclosporin looks like a good match-up against a market-leader Enbrel and a viable Systemic therapy option instead of Cyclosporin (which is considered very effective but cannot be used long-term) with good Efficacy and better safety factors than Cyclosporin. Recent research also linking Psoriasis with hypertension / diabetes also a factor, another advantage for Voclo over Cyclosporin.
I also didn't realize that Cellcept/MMF is also used in Psoriasis treatment (one aspect it reduces Hypertension), perhaps another factor with Roche.
Long-Term Reasearch info (Sept/2008)
https://www3.interscience.wiley.com/cgi-bin/fulltext/121372232/PDFSTART
Up-to-date Psoriasis Treatment (Last updated Apr 27/2009)
https://www.uptodate.com/home/content/topic.do?topicKey=pri_derm/12971
Psoriasis Guidelines - May 2008, Interesting about Raptiva comments (before it was off market)
https://www.aad.org/education/grants/_doc/Psosection1.pdf
Poster for Enbrel/Raptiva (shows comparison of Psoriasis therapies along with Biologics)
https://www.york.ac.uk/inst/crd/Posters/Etanercept%20and%20Efalizumab%20for%20the%20treatment%20of%20moderate%20to%20severe%20psoriasis.pdf